LEO Pharma

LEO Pharma further Boosts Focus on Translational Medicine with the Appointment of Thomas Hultsch, M.D., Ph.D., as Head of Translational Medicine

Share

Ballerup, Denmark, 28 January, 2019 – LEO Pharma, a global leader in medical dermatology, today announced that Thomas Hultsch, M.D., Ph.D., has been appointed as Head of Translational Medicine as of 28 January, 2019.

Thomas Hultsch’s primary task will be to build LEO Pharma’s foothold in Translational Medicine across the US and Europe and lead the establishment of a new Translational Medicine group in Boston.

The appointment of Thomas Hultsch underpins LEO Pharma’s objective to take the global lead in translational dermatology and immunology, among other by strengthening the way the company uses novel technologies in building a precision medicine platform, and by translating scientific and patient insights to further build the company’s disease understanding. Earlier this month, LEO Pharma also announced the appointment of Adam B. Raff, M.D., Ph.D., as Director and Medical Advisor in Translational Medicine.

“At LEO Pharma, we work relentlessly to help patients with skin diseases. We are driven by our desire to offer new, innovative medicines better and faster than anyone else, and our aspiration is to help 125 million patients by 2025. The addition of the new unit in Boston will boost our position in Translational Medicine and help us achieve exactly that. It will strengthen LEO Pharma as a science driven organization by increasing our level of science and dermatology knowledge and thus enable us to explore cutting edge technologies in patients more rapidly,” said Kim Kjoeller, Executive Vice President for Global Research and Development at LEO Pharma.

“Thomas Hultsch comes to LEO Pharma with an extensive network within immune dermatology in the US and Europe as well as an impressive track record of initiating successful scientific collaborations. With his appointment as Head of LEO Pharma’s new Translational Medicine Unit in Boston, we are ready to take translational medicine at LEO Pharma to the next level in terms of being a science driven and patient focused company,” said Per Sproegel, Vice President, Medical Science at LEO Pharma.

Thomas Hultsch is a Doctor of Medicine, a board-certified Dermatologist and Allergist and received his venia legendi for immunology from the Johannes Gutenberg University in Mainz, Germany. He trained as a post-doc and fellow at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland focusing on molecular biology, cell biology and clinical immunology/allergy.

He comes from a position as Senior Director for Translational Medicine at Sanofi US, where he successfully built and operationalized a translational medicine team and brings a wealth of research experience to LEO Pharma, including five years of basic research and more than 15 years of clinical research from different positions in the area of inflammatory diseases in the US and Europe.

“I am thrilled to join LEO Pharma at a time of break-through discoveries in multiple areas of skin biology and technology , providing unparalleled opportunities to drive innovation in dermatology for the benefit of patients world-wide,” said Thomas Hultsch, Head of Translational Medicine, LEO Pharma, Boston, MA.

Contacts

For further information, please contact:

LEO Pharma A/S
Henrik Kyndlev, Global External Communications
hdtdk@leo-pharma.com
Tel.: +45 3140 6180

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. ​Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. ​LEO Pharma is headquartered in Denmark with a global team of 5,700 people, serving 80 million patients in 130 countries. In 2017, the company generated net sales of euro 1.4 billion. ​

Website: www.leo-pharma.com

LinkedIn: www.linkedin.com/company/leo-pharma YouTube: www.youtube.com/leopharmaglobal

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma A/S acquires rights to develop and market brodalumab for moderate-to-severe psoriasis outside of Europe13.8.2019 11:30:00 CESTPress release

New sub-licensing agreement allows LEO Pharma to help more people around the world with an additional treatment option for psoriasis. August 13th, 2019, Ballerup, Denmark: LEO Pharma A/S, a global leader in medical dermatology, today announced it has acquired the exclusive rights to develop and market brodalumab (marketed as Kyntheum® in the European Union) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licencing agreement with Bausch Health Ireland Limited. The new agreement includes countries with significantly high unmet need, such as Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia. This complements the ongoing licensing agreement between LEO Pharma A/S and AstraZeneca to develop and market brodalumab for the treatment of moderate-to-severe psoriasis in Europe. To date, LEO Pharma A/S has successfully launched brodalumab in 18 countries. Outside of the EU, Bausch Health Companies Inc. through a licensing agreement with AstraZeneca, ha

LEO Pharma completes the acquisition of Bayer’s pre-scription dermatology business2.7.2019 09:00:00 CESTPress release

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma. The companies first announced the proposed transaction on July 31, 2018 and completed the first step of the acquisition with the closing in the United States on September 4, 2018. Today’s second and final closing covers all other countries.

LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management10.5.2019 10:27:35 CESTPress release

Ballerup, Denmark, May 10, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced the appointment of Beth-Anne Lang, Vice President and Head of Global Regulatory Affairs and Christine Garrett, Vice President and Head of Global Project Manage-ment. Both will join LEO Pharma on May 13.

New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis25.4.2019 09:12:24 CESTPress release

Ballerup, Denmark, April 25, 2019: LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom